The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy

Annals of Oncology

Volumn 8, Issue 9, 1997, Pages 887-892

  Lebeau, B ^a   Depierre, A ^b   Giovannini, M ^c   Riviere A ^d   Kaluzinski, L ^d   Votan, B ^e   Hedouin M ^e   D'Allens, H ^e  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL SAINT JACQUES   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cisplatin; Emesis; Methylprednisolone; Metopimazine; Ondansetron

Indexed keywords

CISPLATIN; CORTICOSTERONE; DOPAMINE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; METOPIMAZINE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; ISONIPECOTIC ACIDS; METHYLPREDNISOLONE; MIDDLE AGED; NAUSEA; NEOPLASMS; ONDANSETRON; PROGNOSIS; QUALITY OF LIFE; VOMITING;

EID: 0030763439     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008276412559     Document Type: Article

References (25)

1. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905-9.
2. Hellenbrecht D, Saller R. Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplastin induced emesis. Arzneimittelforschung 1986; 36: 1845-9.
3. Lebeau B, Depierre A, d'Allens H. Efficacité antiémétique de l'ondansétron: Comparaison randomisée avec l'association alizapride-mèthylprednisolone dans les cancers bronchiques traités par cisplastine. Sem Hop 1991; 67: 1350-7.
4. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplastinum-induced emesis. N Engl J Med 1990; 322: 816-21.
5. Bonneterre J, Chevallier B, Metz R et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063-9.
6. Chevallier B, Marty M, Paillarse JM. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplastin-induced emesis over at least three cycles. Br J Cancer 1994; 70: 1171-5.
7. Hesketh PJ, Harvey WH, Harker WG et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplastin-induced emesis. J Clin Oncol 1994; 12: 596-600.
8. Roila F, Tonato M, Cognetti F et al. Prevention of cisplastin-induced emesis: A double-blind multicenter randomized cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-8.
9. Smith DB, Newlands ES, Rustin GJS et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplastin-containing chemotherapy. Lancet 1991; 338: 487-90.
10. Olver I, Paska W, Depierre A et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 1996; 7: 945-52.
11. Cunningham D, Dicato M, Verweij J et al. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: Ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. Ann Oncol 1996; 7: 277-82.
12. Anonymous. Ondansetron + dexamethasone vs. metoclopramide + dexamethasone + diphenhydramine in prevention of cisplastin-induced emesis. Lancet 1992; 340: 96-9.
13. Herrstedt J, Sigsgaard T, Boesgaard M et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993; 328: 1076-80.
14. Herrstedt J, Handberg J, Sigsgaard T et al. Randomized, double-blind cross-over trial of the antiemetic effect and tolerability of ondansetron (OND) vs. OND plus the dopamine D2 antagonist metopimazine (MPZ) in patients (pts) receiving platinum-based chemotherapy (CT). Ann Oncol 1994; 5 (Suppl 8): 204 (Abstr P1029).
15. Hirsch JD, Lee JT, Grapski R. Quality of life with intravenous ondansetron vs. standard antiemetic therapy in patients receiving emetogenic cancer chemotherapy. Proc Am Soc Clin Oncol 1992; 11: 393 (Abstr 1368).
16. Richard A, Lee J. Using multinational clinical trial data for psychometric evaluations: Item reduction of the functional living index emesis. Qual Life Res 1994; 3: 54-5.
17. Schipper H, Clinch J, McMurray A et al. Measuring the quality of life of cancer patients: The functional living index-cancer: Development and validation. J Clin Oncol 1984; 2: 472-83.
18. Kris MG. Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations. Semin Oncol 1992; 19 (Suppl 10): 61-6.
19. Smyth JF, Coleman RE, Nicolson M et al. Does dexamethasone enhance control of acute cisplastin induced emesis by ondansetron? BMJ 1991; 303: 1423-6.
20. 3 receptors antagonists. Oncology 1992; 49: 263-8.
21. Harousseau JL, Bonneterre J, Zittoun R et al. Comparaison de l'association ondansétron-méthylprednisolone-lorazépam à l'association ondansétron-méthylprednisolone dans la prévention des nausées et vomissements induits par la chimiothérapie chez des patients en échec d'un premier traitement anti-émétique. IXème Congrès Eurocancer 96, Paris, France, 4-6 juin 1996, Abstr III.1.4, p. 398.
22. Cella DF. Methods and problems in measuring quality of life. Support Care Cancer 1995; 3: 11-22.
23. Richard A, Marty M. Etude des facteurs pronostiques des vomissements induits par les chimiothérapies anticancéreuses chez 2041 patients. Cah Oncol 1993; 2: 175-80.
24. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992; 19 (Suppl 15): 26-32.
25. Marty M. Nausées et vomissements chimio-induits: de l'expérimentation à l'expérience. Bull Cancer 1996; 83: 1014-8.